Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 InterMune, Roche Close HCV Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News

InterMune, Roche Close HCV Agreement

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

InterMune, Inc. has closed its exclusive license and collaboration agreement with Roche for the exclusive worldwide development and commercialization of InterMune’s hepatitis C virus (HCV) protease inhibitor program. The parties received notice of early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, on October 30th.

As a result of the closing, InterMune will receive an upfront payment of $60 million. Roche is now funding 67% of the global development costs associated with ITMN-191, InterMune’s lead HCV protease inhibitor drug candidate. If the development and commercialization of ITMN-191 is successful, InterMune could receive as much as $470 million in milestones, including a potential $35 million within the next 12 months.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters